DGX vs WST: Which Stock Is the Better Buy?
Quest Diagnostics Incorporated and West Pharmaceutical Services, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — DGX vs WST, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Quest Diagnostics Incorporated (DGX) | West Pharmaceutical Services, Inc. (WST) | |
|---|---|---|
| Market cap | $25.7B | $24.0B |
| Revenue (latest FY) | $11.04B | $3.07B |
| Net income (latest FY) | $992.00M | $493.70M |
| Revenue growth (5y CAGR) | 3.2% | 7.4% |
| Net margin | 9.0% | 16.1% |
| Return on equity | 13.8% | 15.5% |
| P/E ratio | 24.8 | 43.7 |
| Dividend yield | 1.5% | 0.3% |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full DGX vs WST breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open DGX's full financials → Open WST's full financials →Frequently asked questions
Which is bigger, DGX or WST?
Quest Diagnostics Incorporated is larger by market capitalization — $25.7B versus $24.0B.
Which grows faster, DGX or WST?
Over the last five fiscal years, West Pharmaceutical Services, Inc. grew revenue faster — 7.4%/yr versus 3.2%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
DGX fundamentals → · WST fundamentals → · All 1,500+ companies → · Free screener →